GANXHealthcare · BiotechnologyGANX Stock Forecast: Gain Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Gain Therapeutics, Inc. hold a median 12-month price target of $8 — +299.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 21 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
GANX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Gain Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (77): Smaller than most of the companies we track.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GANX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GANX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +299.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | BTIG | Reiterates | Buy | $5.00 |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2026 | BTIG | Maintains | Buy | $5.00 |
| 30 June 2026 | BTIG | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Oct 2025 | BTIG | Reiterates | Buy | — |
| 13 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2025 | Maxim Group | Maintains | Buy | — |
| 8 Sept 2025 | BTIG | Reiterates | Buy | — |
| 13 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 3 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 24 Dec 2024 | Roth MKM | Maintains | Buy | — |
| 5 Dec 2024 | Roth MKM | Initiates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GANX appears on the weeks it earns a place.
GANX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Gain Therapeutics, Inc. (GANX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.2×
- Price / sales
- —
- Price / book
- 7.6×
- EV / EBITDA
- −3.8×
Cheaper than 88% of US stocks
Cheaper than 14% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −268.3%
- Return on assets
- −95.5%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GANX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Gain Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GANX stock
What is the GANX stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Gain Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GANX stock a buy right now?
Of the 5 analysts covering Gain Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Gain Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GANX?
As at 21 Aug 2026, Gain Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).
Will GANX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +299.0% from the last close, and Ticker Nerd's factor model ranks Gain Therapeutics, Inc. 29 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GANX stock forecast for 2030?
No analyst covering Gain Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
How has GANX stock performed over the past year?
Gain Therapeutics, Inc. returned +10.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Gain Therapeutics, Inc. do?
Gain Therapeutics Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics.
About Gain Therapeutics, Inc.
Gain Therapeutics Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics. At the heart of its operations is the proprietary SEE-Tx platform, which enables the identification of previously undruggable targets across a range of diseases, primarily focusing on rare genetic disorders and neurological conditions. By analyzing structural proteins, the company aims to address unmet medical needs in areas such as neurodegenerative diseases, offering potential breakthroughs in treatment options. Gain Therapeutics’ emphasis on protein misfolding disorders underscores its impact on critical therapeutic areas, significantly influencing drug research and development in the biotech sector. The company's efforts contribute to redefining therapeutic approaches, ensuring its relevance and importance in the competitive landscape of medical innovations. Gain Therapeutics, by leveraging cutting-edge technology, positions itself as a transformative entity in the medical field, driving forward advancements in patient care for complex diseases.
CEO Mr. Gene Mack M.B.A. · 20 employees · United States · https://gaintherapeutics.com